Clinical experience of the Zydena drug in the therapy of erectile dysfunction
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to evaluate the efficacy and tolerability of the drug udenafil (ZYDENA), 100 mg tablets in the treatment of erectile dysfunction compared with the efficacy and tolerability of the reference drug (Sildenafil).
Materials and methods. The clinical efficacy and safety of the ZYDENA drug in the treatment of erectile dysfunction in a clinical group of 35 patients with ED of mixed origin was studied. The control group included 30 patients who received Sildenafil therapy. Efficiency monitoring was carried out using the questionnaire on the scale of ICEF and dopplerography.
Results. The excellent effect of therapy with udenafil was noted in 26 patients (74.3%), good – in 8 patients (22.8%), in one patient (2.9%) the effect was considered satisfactory. The final evaluation of the therapeutic efficacy showed «excellent» and «good» results in 97.1% of patients.
Conclusions. The prescription of ZYDENA drug to patients with erectile dysfunction (100 mg) leads to a significant increase in integration parameters in 2 2.5 times, which is 1.15 1.25 times higher than in patients who used the drug Sildenafil. The clinical efficacy and safety of Zydena in the treatment of erectile dysfunction on a group of 35 patients with ED of mixed origin was studied. The control group consisted of 30 patients receiving therapy with Sildenafil. The effectiveness was monitored using a questionnaire on the ICEF scale and dopplerography. Purpose of the drug ZYDENA patients with erectile dysfunction (100 mg each) leads to a significant increase in integration parameters in 2 2.5 times, which is 1.15 1.25 times higher than in patients who used the drug Sildenafil. The clinical efficacy of ZYDENA is 97.1%. According to the duration of the action, ZYDENA is more effective than the reference preparation 2.38 times
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Возіанов О.Ф., Горпинченко І.І. Досвід застосування віагри в Україні //Сексология и андрологія. – К., 2000. – Вып. 5. – С. 3–5.
Горпинченко И.И. Эректильная дисфункция: диагностика и современные методы лечения // Здоровье мужчины. – 2002. – No 1. – С. 9–11.
Горпинченко И.И., Мирошников Я.О. Эректильная дисфункция. – Л., «Медицина світу».
Бюва Ж. Лечение силденафилом, четырехлетний опыт // Здоровье мужчины. – 2002. – No 2. – С. 11–13.
Bell AS, Palmer MJ. Novel phosphodiesterase type 5 modulators: a patent survey (2008–2010). Expert Opin Ther Pat. 2011;21(10):1631–1641.
Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta analysis. Eur Urol. 2013;63(5): 902–912.
Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553–557.
Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med. 2010;7(5):1928–1936.
Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231–250.
Doh H, Shin CY, Son M, et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA 8159. Arch Pharm Res. 2002;25(6):873–878.
Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946–953.
Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo controlled trial. J Sex Med. 2010;7(6):2209–2216.
Moon DG, Yang DY, Lee CH, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med. 2011; 8(7): 2048–2061.
Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res. 2009;21(2):122–128.
Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double blind, placebo controlled trial. Eur Urol. 2011;60(2):380–387.
Paick JS, Kim SW, Park YK, et al. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sex Med. 2009;6(11):3166–3176.
Ortaз M, Зayan S, Зalisёkan MK, et al. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double blind, placebo controlled study. Andrology. 2013; 1(4): 549–555.
Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE 5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848–854.
Shim HJ, Kim YC, Park KJ, et al. Pharmacokinetics of DA 8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and
intestinal first pass effects. J Pharm Sci. 2003;92(11):2185–2195.
Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999; 29(3): 297–310.
Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodi esterase families and the effect of silde nafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A): 3C–12C.
Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001; 65:1–52.
European Associacion of Urology. Pocet Guidelines. 2017 edition.
